Antibody 8ANC195 Reveals a Site of Broad Vulnerability on the HIV-1 Envelope Spike - Wikidata - awgldk - TriplyDB

Antibody 8ANC195 Reveals a Site of Broad Vulnerability on the HIV-1 Envelope Spike

Antibody 8ANC195 Reveals a Site of Broad Vulnerability on the HIV-1 Envelope Spike

http://www.wikidata.org/entity/Q27683540

about

Designing synthetic vaccines for HIV Antibody responses to envelope glycoproteins in HIV-1 infection Virological features associated with the development of broadly neutralizing antibodies to HIV-1 HIV broadly neutralizing antibody targets Vaccine-Elicited Tier 2 HIV-1 Neutralizing Antibodies Bind to Quaternary Epitopes Involving Glycan-Deficient Patches Proximal to the CD4 Binding Site Antigenic properties of the human immunodeficiency virus envelope glycoprotein gp120 on virions bound to target cells Crystal structure, conformational fixation and entry-related interactions of mature ligand-free HIV-1 Env Deconstructing the Antiviral Neutralizing-Antibody Response: Implications for Vaccine Development and Immunity Natively glycosylated HIV-1 Env structure reveals new mode for antibody recognition of the CD4-binding site Antiviral Therapy by HIV-1 Broadly Neutralizing and Inhibitory Antibodies Structural Constraints Determine the Glycosylation of HIV-1 Envelope Trimers Glycan clustering stabilizes the mannose patch of HIV-1 and preserves vulnerability to broadly neutralizing antibodies Composition and Antigenic Effects of Individual Glycan Sites of a Trimeric HIV-1 Envelope Glycoprotein Asymmetric recognition of HIV-1 Envelope trimer by V1V2 loop-targeting antibodies.Computational tools for epitope vaccine design and evaluation HIV-1 Glycan Density Drives the Persistence of the Mannose Patch within an Infected Individual.Antibody 10-1074 suppresses viremia in HIV-1-infected individuals Eliciting neutralizing antibodies with gp120 outer domain constructs based on M-group consensus sequence.Broad and potent HIV-1 neutralization by a human antibody that binds the gp41-gp120 interface.Neutralizing Monoclonal Antibodies to Fight HIV-1: On the Threshold of Success.Glycosylation of the core of the HIV-1 envelope subunit protein gp120 is not required for native trimer formation or viral infectivity.Enhanced potency of a broadly neutralizing HIV-1 antibody in vitro improves protection against lentiviral infection in vivo.Drift of the HIV-1 envelope glycoprotein gp120 toward increased neutralization resistance over the course of the epidemic: a comprehensive study using the most potent and broadly neutralizing monoclonal antibodies.Recombinant HIV envelope trimer selects for quaternary-dependent antibodies targeting the trimer apex.Exploring the potential of monoclonal antibody therapeutics for HIV-1 eradication.Two classes of broadly neutralizing antibodies within a single lineage directed to the high-mannose patch of HIV envelope Improving neutralization potency and breadth by combining broadly reactive HIV-1 antibodies targeting major neutralization epitopes.A native-like SOSIP.664 trimer based on an HIV-1 subtype B env gene.Crystal structure of the HIV neutralizing antibody 2G12 in complex with a bacterial oligosaccharide analog of mammalian oligomannose Structure and immune recognition of trimeric pre-fusion HIV-1 Env.Pharmacokinetics and immunogenicity of broadly neutralizing HIV monoclonal antibodies in macaques.Comprehensive antigenic map of a cleaved soluble HIV-1 envelope trimer.Well-ordered trimeric HIV-1 subtype B and C soluble spike mimetics generated by negative selection display native-like properties Antibody engineering for increased potency, breadth and half-life.HIV-1 fitness cost associated with escape from the VRC01 class of CD4 binding site neutralizing antibodies.Single-Chain Soluble BG505.SOSIP gp140 Trimers as Structural and Antigenic Mimics of Mature Closed HIV-1 Env.Characterization of a Large Panel of Rabbit Monoclonal Antibodies against HIV-1 gp120 and Isolation of Novel Neutralizing Antibodies against the V3 Loop.Neutralization properties of simian immunodeficiency viruses infecting chimpanzees and gorillas.The Broad Neutralizing Antibody Responses after HIV-1 Superinfection Are Not Dominated by Antibodies Directed to Epitopes Common in Single Infection HIV-1 VACCINES. Diversion of HIV-1 vaccine-induced immunity by gp41-microbiota cross-reactive antibodies.

P2860

Q26862617-D0FB88FC-B6D1-4D99-A6D9-F2A823039707 Q26991572-43FCDA02-86C6-450C-9F83-AEF8A9651B1E Q27025177-17175DB0-2D07-47CF-B843-DB177789AA48 Q27026662-0A8B8F74-5FDF-4F04-9354-5BCCA77DB5DA Q27319450-CC4A1CEF-5B16-438D-BA29-7AB37C118107 Q27320687-5FAE0ED2-68DC-4325-96A9-B65DE15A6658 Q27644383-23C6FAE0-E2F9-4134-A85D-4494AECB1076 Q27654848-BF2F30F2-995D-4E85-A96E-93D107309C09 Q27728037-F92639BD-9593-4889-A6C2-AE5D4C82F9D0 Q28066335-9BD690CD-3904-42E5-B832-37B302AA455E Q28263063-F207AC9E-6072-47A0-9F3B-1901D58F9FD1 Q28263932-F59A63AE-45A4-44D5-9980-14BD73B33C31 Q29306052-A2BEE3AE-F69C-4AF4-AAF3-46790343CCBF Q30352300-258851F4-231B-4C51-A390-081C7F3402BF Q30373339-0B72A329-B433-4D0F-AB53-CB5C043A5068 Q30393763-866BE419-7C83-4432-A598-14A4D3BF34B6 Q33786443-5CECA2F6-5123-41FB-B9E3-C652BD4D9A8C Q34016706-0DF1D0C0-9DF3-4922-B129-D900A298A162 Q34473958-628567A1-4B81-4F7B-9842-E1C3C13C6F49 Q34550046-D155DA8F-35E6-446D-A86C-A4A63CCC5C0A Q34555891-F926283C-DD5D-4579-A62B-B838310FE81C Q34593860-5626E990-5E2E-4223-B55A-FDB7C785F214 Q34594036-417C076A-6818-4B1A-97F8-191D17106F6D Q34709433-D5F56D43-68D1-44F1-A32B-08DF0D475001 Q34869927-326E2733-27E3-416F-9F0E-624CF05E90A5 Q34991017-E62B3756-CBCA-4103-8C87-1083FAF994AF Q35076711-50D5935D-4733-4174-96FE-CC19B4F4D868 Q35110976-EAFE01E0-B91A-4183-819F-4CBE015FFB06 Q35119778-747B2370-C4F7-403B-9DD4-592B49D61092 Q35142291-5F74E2CA-F86C-470A-93BA-85436A219C0E Q35216862-673794A1-F53A-4CB2-A463-F90557C94E6A Q35217426-09CCEA54-368B-4285-B723-58082EB946A6 Q35540033-529EC8C4-617E-4698-BE79-7792C6E2F67D Q35575206-6A7DDC26-587F-4746-8B42-83B8E54183F9 Q35640998-F2578E89-664C-461E-BCCF-253AF11279A2 Q35641498-8535344A-18D7-4ECD-BE01-AD938FA30AFF Q35651494-12368B09-9312-4EB2-80E9-6ED673206366 Q35677620-70BA07AF-1108-466A-B08F-8C73977A0250 Q35686970-9E2326F7-A6D1-4ECC-AD34-A1689CBFAC83 Q35728947-A012DFE0-99D2-4454-8446-5F74D94B31C5

P2860

Antibody 8ANC195 Reveals a Site of Broad Vulnerability on the HIV-1 Envelope Spike

http://www.wikidata.org/entity/Q27683540

description

2014 nî lūn-bûn

@nan

2014 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Antibody 8ANC195 Reveals a Site of Broad Vulnerability on the HIV-1 Envelope Spike

@ast

Antibody 8ANC195 Reveals a Site of Broad Vulnerability on the HIV-1 Envelope Spike

@en

Antibody 8ANC195 Reveals a Site of Broad Vulnerability on the HIV-1 Envelope Spike

@nl

type

label

Antibody 8ANC195 Reveals a Site of Broad Vulnerability on the HIV-1 Envelope Spike

@ast

Antibody 8ANC195 Reveals a Site of Broad Vulnerability on the HIV-1 Envelope Spike

@en

Antibody 8ANC195 Reveals a Site of Broad Vulnerability on the HIV-1 Envelope Spike

@nl

prefLabel

Antibody 8ANC195 Reveals a Site of Broad Vulnerability on the HIV-1 Envelope Spike

@ast

Antibody 8ANC195 Reveals a Site of Broad Vulnerability on the HIV-1 Envelope Spike

@en

Antibody 8ANC195 Reveals a Site of Broad Vulnerability on the HIV-1 Envelope Spike

@nl

P1433

Q27683540-1EE55345-144B-47FB-8634-D237C911C501

P1476

Q27683540-0E6263A9-C8E1-491B-BE54-FCE8016750F3

P2093

Q27683540-276A9D76-1EF5-4E2F-BD72-5FDD4D185FF8

Q27683540-336A04FD-CA54-468F-97EA-1FA1B7F70A8F

Q27683540-40C96D04-3B57-47C7-BDE5-6D74D2C2F64A

Q27683540-55F649E1-E914-453C-A8E1-F64BF87042C2

Q27683540-67AE7535-B74D-4CD3-B64A-8BDEDD084AF9

Q27683540-A0F3F24D-C87F-411A-B838-97815F82158F

Q27683540-AC21D114-20D3-47F6-A2DA-695887C6105D

Q27683540-B6933626-E5B5-4F31-BE2A-2A4CD1970737

Q27683540-E354687B-6C97-43E8-85AE-1D85AF213395

P2860

Q27683540-00616F38-EA3D-4D76-A856-754082614D96

Q27683540-044699CF-5997-472C-86F4-3518F3788C6C

Q27683540-07EE3607-89DC-479B-92BB-30D0791E1EE5

Q27683540-0E3FBB31-9FDF-41F3-8655-ED2234282794

Q27683540-1A44995A-DCFF-4146-B9C6-DE25A53774CB

Q27683540-1F6BE0BD-E314-4A9A-B874-BB9FF526BE9A

Q27683540-22D369E0-F03E-41A9-A911-97B9AA8AE69E

Q27683540-23CB7FAA-B6FD-4D9D-8EFD-6C004AC73651

Q27683540-2852221D-D68B-4AA1-9BC9-48E02A1156AC

Q27683540-2956B23E-1848-4817-BAD5-F8B1958DD462

P304

Q27683540-A2D6EE40-E9BA-4E82-9B7D-17F971EB4075

P31

Q27683540-440A3A54-A04F-480A-B010-BC713C0657E5

P3181

Q27683540-E0C97D7B-E968-4A0C-AE1D-A7737C2B1189

P356

Q27683540-C9BD8012-9975-4365-81A0-66C50C4825DE

P433

Q27683540-097C1E5E-EC43-412F-8406-D2EFD8C7AD76

P478

Q27683540-DB9A1F8C-783C-4010-AC15-00946DD84BA7

P50

Q27683540-7AFC8CB5-77C8-4888-8CE1-34A038BEBC19

Q27683540-90097BF4-7EF1-459A-BB3F-58B58709B6FF

Q27683540-EA5990F2-F3A7-4F80-B7AC-C97A3D70B7FB

P577

Q27683540-5EB96FB0-4350-4694-8B20-264B1233EB04

P5875

Q27683540-BFC96BD6-5C7B-4DD8-B20B-0693EB4436FF

P698

Q27683540-400AA1E1-F70E-43E4-8FD1-5706DB3642A3

P921

Q27683540-CF218EDB-9BD4-45C6-95D8-6D030D97A00F

P932

Q27683540-21D57575-25E8-4F9B-9F66-5E750D669DE4

P3181

P356

J.CELREP.2014.04.001

P1433

P1476

Antibody 8ANC195 Reveals a Site of Broad Vulnerability on the HIV-1 Envelope Spike

@en

P2093

Andrew B Ward

http://www.w3.org/2001/XMLSchema#string

Anthony P West

http://www.w3.org/2001/XMLSchema#string

Courtney Chen

http://www.w3.org/2001/XMLSchema#string

Han Gao

http://www.w3.org/2001/XMLSchema#string

Johannes F Scheid

http://www.w3.org/2001/XMLSchema#string

Louise Scharf

http://www.w3.org/2001/XMLSchema#string

Michael S Seaman

http://www.w3.org/2001/XMLSchema#string

Priyanthi N P Gnanapragasam

http://www.w3.org/2001/XMLSchema#string

René Mares

http://www.w3.org/2001/XMLSchema#string

P2860

Increasing the potency and breadth of an HIV antibody by using structure-based rational design

PHENIX: a comprehensive Python-based system for macromolecular structure solution

HIV-1 neutralizing antibodies: understanding nature's pathways

Antibodies in HIV-1 vaccine development and therapy

Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9

Molecular architecture of native HIV-1 gp120 trimers

Structure of a clade C HIV-1 gp120 bound to CD4 and CD4-induced antibody reveals anti-CD4 polyreactivity

Sequence and Structural Convergence of Broad and Potent HIV Antibodies That Mimic CD4 Binding

Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies

A Potent and Broad Neutralizing Antibody Recognizes and Penetrates the HIV Glycan Shield

P304

785-95

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

445737

http://www.w3.org/2001/XMLSchema#string

P356

10.1016/J.CELREP.2014.04.001

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P50

Pamela J. Bjorkman

Michel C. Nussenzweig

P577

2014-05-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

261917633

http://www.w3.org/2001/XMLSchema#string

P698

24767986

http://www.w3.org/2001/XMLSchema#string

P921

P932

4109818

http://www.w3.org/2001/XMLSchema#string